Therapy for cystic fibrosis--the end of the beginning?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Imaging of cystic fibrosis manifestations in the abdomen.Abdominal radiology (New York) · 2025
   Review
2. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.Archives of gynecology and obstetrics · 2024
   Review
3. Multicenter Surveillance of Cystic Fibrosis in Korean Children.Allergy, asthma & immunology research · 2022
   Article
4. Stability Prediction for Mutations in the Cytosolic Domains of Cystic Fibrosis Transmembrane Conductance Regulator.Journal of chemical information and modeling · 2021
   Article
5. Cystic fibrosis: a clinical view.Cellular and molecular life sciences : CMLS · 2017
   Review
6. New challenges in the diagnosis and management of cystic fibrosis.The Journal of pediatrics · 2015
   Article
7. A reliable computational workflow for the selection of optimal screening libraries.Journal of cheminformatics · 2015
   Article
8. Ivacaftor: a novel mutation modulating drug.Journal of clinical and diagnostic research : JCDR · 2014
   Review
9. Improving transition from paediatric to adult cystic fibrosis care: programme implementation and evaluation.BMJ quality & safety · 2014
   Article
10. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.Molecular pharmacology · 2013
    Article
11. The effect of whole body vibration exposure on muscle function in children with cystic fibrosis: a pilot efficacy trial.Journal of clinical medicine research · 2013
    Article
12. Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect.Frontiers in pharmacology · 2013
    Article
13. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.Autophagy · 2012
    Article

Corrections and comments

• Comment on
  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as